GlassScriptPhysician profile
Alexander Lakowsky
NPI 1902824550
$3,643.64
in general payments reported to CMS, 2019-2025
33 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $129 · 2021: $645 · 2022: $730 · 2023: $948 · 2024: $493 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,903.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $553.28 | 2019-2025 | Breztri, Airsupra, Andexxa |
| Pfizer INC. | $532.23 | 2019-2025 | |
| Abbvie INC. | $302.56 | 2021-2024 | |
| Novo Nordisk INC | $266.05 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $247.87 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $218.43 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $190.46 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $153.26 | 2022-2024 | Rexulti |
| Astellas Pharma US INC | $151.26 | 2019-2025 | Veozah |
| Abbott Laboratories | $132.26 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Amgen INC. | $93.65 | 2020-2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $72.50 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.88 | 2023-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.10 | 2022-2025 | Jardiance |
| Agios Pharmaceuticals, INC. | $55.07 | 2024-2025 | Pyrukynd |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $54.26 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $54.26 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.77 | 2021-2022 | |
| Allergan, INC. | $42.12 | 2019-2020 | |
| Esperion Therapeutics, INC. | $42.09 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $38.62 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $36.94 | 2019-2025 | Zoryve |
| Ibsa Pharma INC. | $35.57 | 2022 | |
| Bausch Health US, LLC | $35.15 | 2022 | |
| Nabriva Therapeutics, Plc | $23.05 | 2020 | |
| Abiomed | $22.55 | 2024 | Impella |
| Avanir Pharmaceuticals, INC. | $21.53 | 2022 | |
| Amag Pharmaceuticals, INC. | $20.53 | 2020 | |
| Lundbeck LLC | $18.62 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $17.66 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.84 | 2022 | |
| Hikma Pharmaceuticals USA | $13.67 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.55 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Lakowsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.